口腔医学研究 ›› 2018, Vol. 34 ›› Issue (6): 594-596.DOI: 10.13701/j.cnki.kqyxyj.2018.06.005

• 综述 • 上一篇    下一篇

头颈癌化疗耐药相关微小RNA研究进展

尹西腾, 韩伟*   

  1. 南京大学医学院附属口腔医院,南京市口腔医院口腔颌面外科 江苏 南京 210008
  • 收稿日期:2017-05-06 出版日期:2018-06-20 发布日期:2018-06-21
  • 通讯作者: 韩伟,E-mail:doctorhanwei@hotmail.com
  • 作者简介:尹西腾(1992~ ),男,江苏省东海人,硕士在读,研究方向为肿瘤微环境与耐药。
  • 基金资助:
    江苏省自然科学基金优秀青年项目(编号:BK20160051 );南京市卫生局杰出青年基金项目(编号:JQX14010)

Research Progress of MicroRNA Related to Chemotherapy Resistance in Head and Neck Cancer

YIN Xi-teng,HAN Wei*   

  1. Department of Oral and Maxillofacial Surgery, Nanjing Stomatological Hospital, Medical School of Nanjing University, Nanjing 210008, China
  • Received:2017-05-06 Online:2018-06-20 Published:2018-06-21

摘要: 头颈癌(head and neck cancer, HNC)是全球范围内最常见恶性肿瘤之一。目前,以顺铂为核心的化疗和辅助放疗仍是晚期患者的一线治疗方案。然而,患者的治疗效果往往受限于癌细胞对化疗药物的耐受,最终导致治疗失败直至患者死亡。微小RNA(microRNA,miRNA)是一类小分子非编码RNA,近年来研究发现miRNAs在肿瘤进展、转移、侵袭和耐药中都发挥重要作用。有研究结果表明,miRNAs的表达变化可通过多种途径导致头颈癌细胞耐药,其相关机制包括多重耐药(multidrug resistance,MDR)转运蛋白、抗凋亡、DNA损伤修复、上皮-间充质转化(epithelial mesenchymal transformation,EMT)、肿瘤干细胞(cancer stem cells,CSCs)、药物靶点的改变和代谢等。本文将就此进行综述,并探讨利用miRNAs辅助临床化疗的策略。

关键词: 微小RNA, 耐药, 头颈癌

Abstract: Head and Neck Cancer (HNC) is one of the most common malignancies in the world. At present, cisplatin based chemotherapy and adjuvant radiotherapy is still the first-line treatment for advanced patients. However, the treatment effect of patients is often limited by the tolerance of cancer cells to chemotherapy drugs, which ultimately leads to treatment failure and death. In recent years, miRNAs has been found to play an important role in tumor progression, metastasis, invasion, and drug resistance. Through literature review, we found that the expression of miRNAs can lead to head and neck cancer resistance through a variety of ways, including the mechanisms of multidrug resistance (MDR) transporters, anti-apoptosis, DNA damage repair, epithelial mesenchymal transition (EMT), cancer stem cells (CSCs), drug target change, and metabolism. This article reviews and explores the use of miRNAs adjuvant chemotherapy strategy.

Key words: MicroRNA, Drug resistance, Head and neck cancer